Melinta is committed to working with global pharmaceutical companies to extend the development and commercialization of our products to markets around the world and to building our own pipeline of drugs to cure patients suffering from serious infections. To that end, we have signed several mutually beneficial agreements, which are summarized below. We remain interested in exploring opportunities outside of those described in these agreements. If you’d like more information
on how your company can partner with Melinta, please email us at email@example.com.
In March 2017, Melinta licensed rights to delafloxacin (known as Baxdela in the U.S.) to the Menarini Group in 68 countries in Europe, Asia-Pacific, and the Commonwealth of Independent States (CIS) listed below. Together, we will work with Menarini to develop and commercialize delafloxacin for multiple indications including serious skin infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). Under the terms of the collaboration, Menarini will be responsible for submitting regulatory applications and commercializing delafloxacin in the countries being licensed. Melinta received an upfront payment and near-term development and regulatory milestone payments, as well as sales milestones and royalties, and the parties will share in the development costs for future indications going forward. To learn more about Menarini Group, please visit www.menarini.com.
Menarini retains rights in the following countries: Albania, Andorra, Austria, Belgium, Bosnia-Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kosovo, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta, Monaco, Montenegro, the Netherlands, Norway, Poland, Portugal, Romania, San Marino Republic, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, United Kingdom, Vatican City, Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine, Uzbekistan, Australia, China, Hong Kong, India, Indonesia, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam.
In June 2015, Melinta and Malin Plc entered into an agreement for the commercialization and distribution of delafloxacin (known as Baxdela in the U.S.) in certain countries in the Middle East and Africa listed below. Under the terms of their agreement, Melinta gains access to Malin’s global network of biotechnology and pharmaceutical companies, expanding delafloxacin’s commercial potential to include the emerging nations Middle East and Africa. For more information on Malin Plc, please visit www.malinplc.com.
Malin retains rights in the following countries: Algeria, Angola, Benin, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Democratic Republic of the Congo, Djibouti, Egypt, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Ivory Coast, Kenya, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritius, Mauritania, Mayotte, Morocco, Mozambique, Namibia, Niger, Nigeria, Republic of the Congo, Reunion, Rwanda, Saint Helena, Ascension and Tristan da Cunha, Senegal, Sao Tomé and Principe, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Swaziland, Tanzania, Togo, Tunisia, Uganda, Western Sahara, Zambia and Zimbabwe, Bahrain, Cyprus, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Palestine (including West Bank and Gaza), Qatar, Saudi Arabia, Syria, Turkey, United Arab Emirates and Yemen.
In January 2015, Melinta and Eurofarma Laboratórios, one of the largest pharmaceutical companies in Brazil and present in more than 20 countries in Latin America, entered into an agreement for the development and commercialization of delafloxacin (known as Baxdela in the US) in Brazil. In August 2017, the companies amended the agreement to cover all countries in Latin America. Under the terms of the agreements, Eurofarma will be responsible for obtaining regulatory approval in the Territories and will then have the right to market, sell and distribute delafloxacin in these countries. Melinta received a combined upfront cash and equity payment and will receive milestones and royalties on future sales of delafloxacin. To learn more about Eurofarma, please visit www.eurofarma.com.
Eurofarma retains rights in these additional countries: Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Uruguay, and Venezuela.
In December 2014, Melinta entered into a license agreement for the development and commercialization of radezolid in topical formulations for a variety of dermatological indications. Melinta retains the option to co-develop or fully regain rights to radezolid upon completion of specific development milestones. In February 2017, the partners announced that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application, and that the partners would be collaborating on the design and implementation of a clinical development plan for topical radezolid for the treatment of mild-to-moderate acne. Radezolid for acne vulgaris has now successfully completed a Phase 1 trial and a Phase 2 study is underway.
We have licensed solithromycin to Toyama Chemical Co., Ltd., or Toyama, for development and commercialization in Japan while retaining the rights to the rest of the world. Toyama has successfully completed a Phase 1 trial in healthy Japanese volunteers, a Phase 1 trial to measure solithromycin levels in the upper respiratory tract, and a Phase 2 trial in CABP. In December 2016, Toyama initiated Phase 3 trials in patients infected with CABP and other respiratory infections. Toyama and we are sharing the results of our respective development activities.
Please contact us at Melinta should you be interested in exploring partnering potential on our assets outside our existing partnerships.